The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing.

Abstract

Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better understand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.

• Authors: Hazel Dunbar, Daniel J Weiss, Sara Rolandsson Enes, John G Laffey, Karen English
• Journal: Cells (Cells) Vol. 10 Issue 11 (11 02 2021) ISSN: 2073-4409 [Electronic] Switzerland
• PMID: 34831203 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Animals
• Humans
• Inflammation (pathology)
• Lung (pathology)
• Mesenchymal Stem Cell Transplantation
• Mesenchymal Stem Cells (pathology)
• Translational Research, Biomedical
• Treatment Outcome